Fig. 2From: Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasmsFunctional selectivity of ZT55 characterized with cell proliferation and viability in cancer cells. (a) To determine the cell proliferation IC50 values, cells were treated for 48 h with various concentrations of ZT55 and their viability tested with CellTiter-Glo Assay. The mean IC50 results were calculated from three independent experiments. The error bars on bar graph denote mean ± SEM (n = 3). (b) Representative images were HEL cells under a phase contrast microscope after treating with ZT55 (0, 12.5, 25 or 50 μM) in 96-well plates for 24 h. Scale bar = 100 μm. (c) Analysis of HEL cells treated with certain concentrations of ZT55 at different time points (24, 48 and 72 h) were performed by CellTiter-Glo assay. The relative cell viability is shown as means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001)Back to article page